Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.

Thorsten M. Seyler, Riyaz H. Jinnah, L. Andrew Koman, David R. Marker, Michael A. Mont, Slif D. Ulrich, Anil Bhave

Research output: Contribution to journalArticle

Abstract

The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalJournal of surgical orthopaedic advances
Volume17
Issue number4
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Knee Replacement Arthroplasties
Type A Botulinum Toxins
Contracture
Injections
Knee
Spasm
Therapeutics
Neuromuscular Blocking Agents
Clubfoot
Articular Range of Motion
Nervous System Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Seyler, T. M., Jinnah, R. H., Koman, L. A., Marker, D. R., Mont, M. A., Ulrich, S. D., & Bhave, A. (2008). Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. Journal of surgical orthopaedic advances, 17(4), 231-238.

Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. / Seyler, Thorsten M.; Jinnah, Riyaz H.; Koman, L. Andrew; Marker, David R.; Mont, Michael A.; Ulrich, Slif D.; Bhave, Anil.

In: Journal of surgical orthopaedic advances, Vol. 17, No. 4, 12.2008, p. 231-238.

Research output: Contribution to journalArticle

Seyler, TM, Jinnah, RH, Koman, LA, Marker, DR, Mont, MA, Ulrich, SD & Bhave, A 2008, 'Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.', Journal of surgical orthopaedic advances, vol. 17, no. 4, pp. 231-238.
Seyler, Thorsten M. ; Jinnah, Riyaz H. ; Koman, L. Andrew ; Marker, David R. ; Mont, Michael A. ; Ulrich, Slif D. ; Bhave, Anil. / Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. In: Journal of surgical orthopaedic advances. 2008 ; Vol. 17, No. 4. pp. 231-238.
@article{08dabbf5a2774040ba771cc490152f99,
title = "Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.",
abstract = "The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.",
author = "Seyler, {Thorsten M.} and Jinnah, {Riyaz H.} and Koman, {L. Andrew} and Marker, {David R.} and Mont, {Michael A.} and Ulrich, {Slif D.} and Anil Bhave",
year = "2008",
month = "12",
language = "English (US)",
volume = "17",
pages = "231--238",
journal = "Journal of the Southern Orthopaedic Association",
issn = "1548-825X",
publisher = "Data Trace Publishing Co.",
number = "4",

}

TY - JOUR

T1 - Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.

AU - Seyler, Thorsten M.

AU - Jinnah, Riyaz H.

AU - Koman, L. Andrew

AU - Marker, David R.

AU - Mont, Michael A.

AU - Ulrich, Slif D.

AU - Bhave, Anil

PY - 2008/12

Y1 - 2008/12

N2 - The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.

AB - The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.

UR - http://www.scopus.com/inward/record.url?scp=59449097474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449097474&partnerID=8YFLogxK

M3 - Article

C2 - 19138496

AN - SCOPUS:59449097474

VL - 17

SP - 231

EP - 238

JO - Journal of the Southern Orthopaedic Association

JF - Journal of the Southern Orthopaedic Association

SN - 1548-825X

IS - 4

ER -